A detailed history of Rhumbline Advisers transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 186,898 shares of LCTX stock, worth $93,449. This represents 0.0% of its overall portfolio holdings.

Number of Shares
186,898
Previous 132,491 41.06%
Holding current value
$93,449
Previous $132,000 28.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.8 - $1.12 $43,525 - $60,935
54,407 Added 41.06%
186,898 $170,000
Q2 2024

Aug 01, 2024

BUY
$0.89 - $1.47 $15,495 - $25,594
17,411 Added 15.13%
132,491 $132,000
Q1 2024

May 09, 2024

BUY
$0.86 - $1.48 $3,116 - $5,363
3,624 Added 3.25%
115,080 $170,000
Q4 2023

Feb 08, 2024

BUY
$0.91 - $1.35 $437 - $649
481 Added 0.43%
111,456 $121,000
Q3 2023

Nov 09, 2023

BUY
$1.16 - $1.53 $7,990 - $10,538
6,888 Added 6.62%
110,975 $130,000
Q2 2023

Aug 08, 2023

BUY
$1.26 - $1.53 $131,149 - $159,253
104,087 New
104,087 $146,000
Q2 2022

Aug 11, 2022

SELL
$1.12 - $1.61 $113,951 - $163,804
-101,742 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$1.21 - $2.48 $22,617 - $46,356
-18,692 Reduced 15.52%
101,742 $157,000
Q4 2021

Feb 10, 2022

BUY
$1.84 - $2.68 $3,148 - $4,585
1,711 Added 1.44%
120,434 $295,000
Q3 2021

Nov 12, 2021

BUY
$2.26 - $2.86 $14,030 - $17,754
6,208 Added 5.52%
118,723 $299,000
Q2 2021

Aug 05, 2021

BUY
$2.17 - $3.0 $244,157 - $337,545
112,515 New
112,515 $321,000
Q2 2020

Aug 13, 2020

SELL
$0.71 - $1.18 $128,044 - $212,805
-180,344 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$0.54 - $1.01 $77 - $144
143 Added 0.08%
180,344 $161,000
Q3 2019

Oct 23, 2019

BUY
$0.85 - $1.24 $153,170 - $223,449
180,201 New
180,201 $177,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $84.9M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.